Exploration of epithelial-mesenchymal transition-related lncRNA signature and drug sensitivity in breast cancer

Frontiers in Endocrinology

Endocrinology

Ziyang Di¹  Gaosong Wu²  Gaoran Xu²  Chengxin Li²  Yalong Yang²  Lewei Zheng²  Jinxuan Hou²  Qianqian Yuan²  Xingxing Dong² 

[1] Department of Gastrointestinal Surgery and Department of Gastric and Colorectal Surgical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, China;Department of Thyroid and Breast Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China;

关键词: epithelial-mesenchymal transition;    breast cancer;    long non-coding RNA;    prognostic model;    drug sensitivity;   

DOI  :  10.3389/fendo.2023.1154741

 received in 2023-01-31, accepted in 2023-07-05,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundBreast cancer (BRCA) has become the most diagnosed cancer worldwide for female and seriously endanger female health. The epithelial-mesenchymal transition (EMT) process is associated with metastasis and drug resistance in BRCA patients. However, the prognostic value of EMT-related lncRNA in BRCA still needs to be revealed. The aim of this study is to construct an EMT-related lncRNA (ERL) signature with accuracy predictive ability for the prognosis of BRCA patients.MethodsRNA-seq expression data and Clinical characteristics obtained from the TCGA (The Cancer Genome Atlas) were used in the study. First, we identified the EMT-related lncRNA by the Pearson correlation analysis. An EMT-related lncRNAs prognostic risk signature was constructed using univariate Cox regression and Lasso-penalized Cox regression analyses. The model’s performance was validated using Kaplan-Meier (KM) survival analysis, ROC curve and C-index. Finally, a nomogram was constructed for clinical practice in evaluating the patients with BRCA and validated by calibration curve and decision curve analysis (DCA). We also evaluated the drug sensitivity of signature lncRNA and the tumor immune cell infiltration in breast cancer.ResultsWe constructed a 10-lncRNA risk score signature based on the lncRNAs associated with the EMT process. We could assign BRCA patients to the high- and low-risk group according to the median risk score. The prognostic risk signature showed excellent accuracy and demonstrated sufficient independence from other clinical characteristics. The immune cell infiltration analysis showed that the prognostic risk signature was related to the infiltration of the immune cell subtype. Drug sensitivity analysis proved ERLs signature could effectively predict the sensitivity of patients to common chemotherapy drugs in BRCA and provide guidance for chemotherapy drugs for high-risk and low-risk patients.ConclusionOur ERL signature and nomogram have excellent prognostic value and could become reliable tools for clinical guidance.

【 授权许可】

Unknown   
Copyright © 2023 Li, Zheng, Xu, Yuan, Di, Yang, Dong, Hou and Wu